In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
Saved in:
| Title: | In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding. |
|---|---|
| Authors: | Riaz IB; Mayo Clinic, Rochester, Minnesota, USA (I.B.R., A.L.M.).; University of Kansas School of Medicine, Wichita, Kansas, USA (I.B.R., R.G.B.)., Marshall AL; Mayo Clinic, Rochester, Minnesota, USA (I.B.R., A.L.M.)., Badgett RG; University of Kansas School of Medicine, Wichita, Kansas, USA (I.B.R., R.G.B.). |
| Source: | Annals of internal medicine [Ann Intern Med] 2020 Aug 18; Vol. 173 (4), pp. JC21. |
| Publication Type: | Journal Article; Comment |
| Journal Info: | Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model: Print Cited Medium: Internet ISSN: 1539-3704 (Electronic) Linking ISSN: 00034819 NLM ISO Abbreviation: Ann Intern Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1539-3704 |
|---|---|
| DOI: | 10.7326/ACPJ202008180-021 |
